Compare iShares MSCI Indonesia ETF (EIDO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares MSCI Indonesia ETF trades at $11.84 (market cap $409.22M), while Vertex Pharmaceuticals Incorporated trades at $508.42 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 311.7× iShares MSCI Indonesia ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 75 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EIDO | VRTX | |
|---|---|---|
Market Cap | $409.22M | $127.55B |
Volume | 879,527 | 1,487,944 |
52-Week High | $19.22 | $557.96 |
52-Week Low | $10.80 | $407.37 |
Typical Hold Time | 75 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.82, down 0.34% with bearish technical signals from moving averages. The ETF faces weak price action despite attractive valuation metrics, with technical indicators showing mixed signals including a neutral RSI but bearish ADX readings. Trading volume declined 21% below average, indicating reduced investor interest.
The outlook remains cautious given persistent technical downtrend and Indonesia's limited benefit from commodity gains. While valuation appears attractive at 8.7x P/E, the 44% financials weighting and modest 5.9% long-term EPS growth constrain upside potential. Key risks include sector concentration and regional capital outflows from Asian equities.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
